



New Zealand standardised oral formulation batch sheet

Levothyroxine suspension 25 microgram/mL (80 mL)

NB: Please check strength as there are two

Patient's name		Storage condition	In a refrigerator	At room temperature
NHI		Temperature	2-8°C	≤ 25°C
Date compounded		Shelf life	14 days	7 days
Batch number		Recommended storage	<input checked="" type="checkbox"/>	May be stored at room temperature if this is more practical and temperatures greater than 25°C are avoided

Ingredients required and formula:

Ingredient	Supplier	Batch number	Expiry date	Standard formula	Quantity dispensed	Dispensed by	Checked by
Levothyroxine 100 microgram tablets				20 tablets			
Ora-Blend®	Perrigo			to 80 mL			
OR							
Ora-Plus®	Perrigo			40 mL			
Ora-Sweet®	Perrigo			40 mL			

Ora-Blend SF® or Ora-Sweet SF® (sugar free) can be substituted? Yes

Calculations performed by

Calculations checked by (pharmacist)

Area cleared for processing by

Instructions to compound suspension:

1. **If Ora-Blend® unavailable:** Pre-mix the Ora-Plus® and Ora-Sweet® to form the diluent.
2. Crush tablets in mortar to a fine powder.
3. Add diluent (Ora-Blend® or prepared diluent) to form a smooth paste.
4. Gradually add the diluent and transfer to the final measuring flask, rinsing the mortar well. Mix well.
5. Make up to the final volume and mix well.
6. Label and package product appropriately.

Labels

Attach product label and auxiliary labels:

Label checked by



New Zealand standardised oral formulation batch sheet

Levothyroxine suspension 25 microgram/mL (80 mL)

NB: Please check strength as there are two

Final yield	_____ mL	Checked by	
Final appearance of product	Pale white suspension.		
Container	Amber plastic mission bottle.		
Compounded by	<i>Name:</i>	<i>Signature:</i>	<i>Date:</i>
Final check and product release	<i>Name:</i>	<i>Signature:</i>	<i>Date:</i>
Special instructions: <ol style="list-style-type: none">1. Shake well before use.2. Store in a refrigerator.3. Synthroid® 25 microgram tablets may be crushed if appropriate - see notes in the New Zealand Formulary for Children (NZFC).			
References: <ol style="list-style-type: none">1. Nahata MC. <i>Int J Pharm Compd</i>, 2015; 19(5): 428-431.			
Prepared by	New Zealand Compounding Working Group		
Approved by	Medication Safety Expert Advisory Group of Health Quality and Safety Commission NZ		
Hosted by	Pharmaceutical Society of New Zealand Standard Formulations in the Practice Support section of the PSNZ website		
Version number	2.0	Version approval date	17/07/19
Document review due	01/08/21		

Disclaimer: this batch sheet has been designed to provide guidance and standardised formulations for New Zealand pharmacists. Please read and familiarise yourself with the general guidance for compounding oral liquids (available on the PSNZ web site) before use. Information was considered accurate at the time of publication.